Royalty Pharma plc (RPRX) Files 8-K

TL;DR

RPRX filed an 8-K confirming HQ and Nasdaq listing. Business as usual.

AI Summary

On January 10, 2025, Royalty Pharma plc (RPRX) filed an 8-K report. The filing confirms the company's principal executive offices are located at 110 East 59th Street, New York, New York, 10022. Royalty Pharma plc is incorporated in England and Wales and its Class A Ordinary Shares trade on The Nasdaq Stock Market LLC under the symbol RPRX.

Why It Matters

This 8-K filing serves as a routine update for investors, confirming key corporate information and the trading status of Royalty Pharma's shares on Nasdaq.

Risk Assessment

Risk Level: low — This filing is a standard corporate disclosure and does not contain any new material information that would inherently increase risk.

Key Players & Entities

• Royalty Pharma plc (company) — Registrant
• RPRX (company) — Trading Symbol
• January 10, 2025 (date) — Date of Report
• 110 East 59th Street, New York, New York, 10022 (location) — Principal executive offices
• England and Wales (location) — Jurisdiction of incorporation
• The Nasdaq Stock Market LLC (company) — Exchange

FAQ

Key Financial Figures

• $0.0001 — ed Class A Ordinary Shares, par value $0.0001 per share RPRX The Nasdaq Stock Marke
• $200,000,000 — in the Transaction will consist of (i) $200,000,000 of cash, less the aggregate amount of m
• $380 million — n, RPH agreed to assume RP Management's $380 million term loan facility and all outstanding
• $3 billion — at the Company Board has approved a new $3 billion share repurchase program. The full text
• $3 billion — ase Agreement and the approval of a new $3 billion share repurchase program. The full text

Filing Documents

• dp223331_8k.htm (8-K) — 46KB
• dp223331_ex0201.htm (EX-2.1) — 644KB
• dp223331_ex9901.htm (EX-99.1) — 47KB
• dp223331_ex9902.htm (EX-99.2) — 38KB
• dp223331_ex9903.htm (EX-99.3) — 38KB
• ex9902_001.jpg (GRAPHIC) — 41KB
• ex9902_002.jpg (GRAPHIC) — 151KB
• ex9902_003.jpg (GRAPHIC) — 1002KB
• ex9902_004.jpg (GRAPHIC) — 932KB
• ex9902_005.jpg (GRAPHIC) — 98KB
• ex9902_006.jpg (GRAPHIC) — 386KB
• ex9902_007.jpg (GRAPHIC) — 371KB
• ex9902_008.jpg (GRAPHIC) — 349KB
• ex9902_009.jpg (GRAPHIC) — 362KB
• ex9902_010.jpg (GRAPHIC) — 257KB
• ex9902_011.jpg (GRAPHIC) — 105KB
• ex9902_012.jpg (GRAPHIC) — 316KB
• ex9902_013.jpg (GRAPHIC) — 314KB
• ex9902_014.jpg (GRAPHIC) — 322KB
• ex9902_015.jpg (GRAPHIC) — 320KB
• ex9902_016.jpg (GRAPHIC) — 97KB
• ex9902_017.jpg (GRAPHIC) — 251KB
• ex9902_018.jpg (GRAPHIC) — 413KB
• image_001.jpg (GRAPHIC) — 4KB
• image_002.jpg (GRAPHIC) — 1KB
• image_003.jpg (GRAPHIC) — 2KB
• 0000950103-25-000393.txt ( ) — 9557KB
• rprx-20250110.xsd (EX-101.SCH) — 3KB
• rprx-20250110_lab.xml (EX-101.LAB) — 33KB
• rprx-20250110_pre.xml (EX-101.PRE) — 22KB
• dp223331_8k_htm.xml (XML) — 3KB

02 Unregistered Sales of Equity Securities

Item 3.02 Unregistered Sales of Equity Securities The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. The issuance of the Share Consideration (and any shares of the Company issuable upon the redesignation of the Share Consideration) to the Sellers will be completed in reliance upon the exemption from the registration requirements of the Securities Act of 1933, as amended, provided by Section 4(a)(2) thereof as a transaction by an issuer not involving any public offering. The Company will rely on this exemption from registration based in part on representations made by the Seller. Item7.01. Regulation FD Disclosure. Press Release On January 10, 2025, the Company issued a press release announcing the entry by the Company into the Purchase Agreement and that the Company Board has approved a new $3 billion share repurchase program. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Investor Presentation On January 10, 2025, the Company posted on its website, www.royaltyphrama.com, under "Investors," an investor presentation (the "Investor Presentation"). A copy of the Investor Presentation that was posted by the Company is furnished as Exhibit 99.2 hereto and is incorporated in this Item 7.01 by reference. The information included under Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2, shall not be incorporated by reference into any filing under the Securities Act or the Exchange Act, unless specifically incorporated by reference into any such filing. Transcript of Investor Call On January 10, 2025, the Comp

SIGNATURES

SIGNATURES Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ROYALTY PHARMA PLC Date: January 10, 2025 By: /s/ Terrance Coyne Terrance Coyne Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR